ALK-Positive Lung Cancer: What the Research Shows

ALK-positive lung cancer refers to non-small cell lung cancer driven by a rearrangement in the ALK gene, a subtype that makes up a small percentage of NSCLC cases but occurs more often in younger patients and never-smokers.

An ALK gene 'rearrangement' occurs when the ALK gene fuses abnormally with another gene, producing a protein that drives uncontrolled cell growth. Unlike a simple point mutation, this is a structural rearrangement of genetic material, which is why it's usually described as a 'fusion' or 'rearrangement' rather than a mutation.

ALK-positive lung cancer tends to occur in a demographic pattern distinct from smoking-related lung cancer generally: more often in younger patients and in people who have never smoked. This has made it a focus of targeted-therapy research aimed specifically at blocking the abnormal ALK fusion protein.

Because ALK rearrangements are relatively uncommon, research in this area often relies on multi-institution trial networks to enroll enough patients for meaningful studies — a pattern also seen with other less-common driver mutations like ROS1 and MET exon 14.